To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen
administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).
To be eligible
- participants will have Type 1 diabetes, diagnosed within the previous 12 months and
established by standard American Diabetes Association criteria.
- All participants will have autoantibodies: either anti-GAD65, anti-ICA512, or if
treated with insulin for less than 7 days, anti-insulin.
- The age range will be between 8 and 30 years; and
- a minimum weight of 34 kg.